135O - Antiangiogenic activity of Annona muricata (soursop) leaf extract (135O)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Developmental therapeutics
Topics Drug Development
Basic Science
Presenter Claudine Candy Cauilan
Citation Annals of Oncology (2017) 28 (suppl_10): x39-x41. 10.1093/annonc/mdx658
Authors C.C. Cauilan1, M.T. Amil1, C.A. Condalor1, K.M. Orodio1, V.E. Santos1, A. Teves1, M.O. Igot2
  • 1College Of Medical Laboratory Science, De La Salle Health Sciences Institute- Dasmarinas City, 4114 - Dasmarinas City/PH
  • 2Oncology, De La Salle University Medical Center, 4114 - Dasmarinas City/PH



The use of food supplements as a treatment for cancer in the Philippines has been competing with surgery, chemotherapy, and radiation therapy, which are the standard treatment. For the past years, Annona muricata (soursop) supplements have dominated the market after a paper from the Philippine Department of Science and Technology revealed that it has anti-angiogenic activity on chick chorioallantoic angiogenic (CAM) assays. However, to date, there are no human cancer studies to support this claim. This study aimed to compare the level of anti-angiogenic activity of A. muricata leaf extracts with bevacizumab, a pure anti-angiogenic drug and paclitaxel, a chemotherapy agent with an anti-angiogenic property on CAM assays.


Ninety-six duck embryos were inoculated with A. muricata 40 ug, paclitaxel 0.92 ug, bevacizumab 238 ug, and 0.2% dimethylsulfoxide (DMSO), the latter serving as the negative control. Angiogenesis was evaluated by counting the branching points using the WIMASIS image analysis web-based system. Multiple comparisons within groups was done using Tukey-Kramer HSD test at an α of 0.05 with 80% statistical power.


Mean branching points for A. muricata, paclitaxel, bevacizumab and DMSO were 117.71, 9.29, 2.54 and 158.46. A. muricata leaf extracts showed a significant difference with paclitaxel (mean difference=108.42, p=.000), bevacizumab (mean difference=115.167, p=.000) and DMSO (mean difference= -40.75, p=.000).


Bevacizumab and paclitaxel are far better anti-angiogenic agents than A. muricata extracts on CAM assays. While these are not human studies, our study clearly shows the superiority of bevacizumab and paclitaxel.

Legal entity responsible for the study

De La Salle University Manila- Chemical Engineering Department

Clinical trial identification

Legal entity responsible for the study

De La Salle University Manila- Chemical Engineering Department




All authors have declared no conflicts of interest.